Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
47.03
-2.22 (-4.51%)
At close: Feb 12, 2026, 4:00 PM EST
46.76
-0.27 (-0.57%)
Pre-market: Feb 13, 2026, 7:19 AM EST
Sanofi Employees
Sanofi had 82,878 employees as of December 31, 2024. The number of employees decreased by 3,210 or -3.73% compared to the previous year.
Employees
82,878
Change (1Y)
-3,210
Growth (1Y)
-3.73%
Revenue / Employee
$661,820
Profits / Employee
$110,686
Market Cap
113.47B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
| Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
| Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
| Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
| Dec 31, 2020 | 99,412 | -997 | -0.99% |
| Dec 31, 2019 | 100,409 | -3,817 | -3.66% |
| Dec 31, 2018 | 104,226 | -2,340 | -2.20% |
| Dec 31, 2017 | 106,566 | -293 | -0.27% |
| Dec 31, 2016 | 106,859 | -2,230 | -2.04% |
| Dec 31, 2015 | 109,089 | 1,702 | 1.58% |
| Dec 31, 2014 | 107,387 | -4,741 | -4.23% |
| Dec 31, 2013 | 112,128 | 154 | 0.14% |
| Dec 31, 2012 | 111,974 | -1,745 | -1.53% |
| Dec 31, 2011 | 113,719 | 12,144 | 11.96% |
| Dec 31, 2010 | 101,575 | -3,292 | -3.14% |
| Dec 31, 2009 | 104,867 | 6,654 | 6.78% |
| Dec 31, 2008 | 98,213 | -1,282 | -1.29% |
| Dec 31, 2007 | 99,495 | -794 | -0.79% |
| Dec 31, 2006 | 100,289 | 3,108 | 3.20% |
| Dec 31, 2005 | 97,181 | 742 | 0.77% |
| Dec 31, 2004 | 96,439 | 63,353 | 191.48% |
| Dec 31, 2003 | 33,086 | 650 | 2.00% |
| Dec 31, 2002 | 32,436 | 1,922 | 6.30% |
| Dec 31, 2001 | 30,514 | 1,314 | 4.50% |
| Dec 31, 2000 | 29,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 92,900 |
| Pfizer | 81,000 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Novo Nordisk | 69,505 |
| GSK plc | 68,629 |
| AbbVie | 55,000 |
| Bristol-Myers Squibb Company | 32,500 |
SNY News
- 6 hours ago - Sanofi's new CEO needs to fix drug pipeline and navigate Trump - Reuters
- 14 hours ago - Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued - Seeking Alpha
- 1 day ago - Who is Sanofi's new CEO Belén Garijo? - Reuters
- 1 day ago - Sanofi Names Merck KGaA's Garijo to Replace Hudson as CEO - WSJ
- 1 day ago - Sanofi appoints Belén Garijo as new CEO after deciding not to renew current CEO Hudson's mandate - Reuters
- 1 day ago - Press Release: Belén Garijo to become Chief Executive Officer of Sanofi - GlobeNewsWire
- 1 day ago - Sanofi: Information concerning the total number of voting rights and shares – January 2026 - GlobeNewsWire
- 2 days ago - Press Release: Sanofi completes the acquisition of Dynavax - GlobeNewsWire